ReST Therapeutics wins FDA IND acceptance for RST-101 as early PTSD treatment strategy enters human testing
ReST Therapeutics’ RST-101 enters human testing for early PTSD. Find out why this IND acceptance could reshape trauma care.
Is lysergide finally going mainstream? Definium Therapeutics bets on DT120 ODT clinical momentum
Can DT120 ODT transform mental health treatment? Explore Definium Therapeutics’ pivotal trials and what they mean for psychedelic psychiatry.
Can TN-001 avoid hallucinogenic pitfalls while delivering rapid antidepressant effects?
Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.